NEXGEL Regains Nasdaq Compliance After Meeting $1 Minimum Bid Price for 10 Days
Key Facts
NEXGEL announced on October 27 that it had regained compliance with Nasdaq’s minimum bid price requirement after its stock closed at $1 or more for 10 consecutive business days. The company confirmed that Nasdaq’s letter closed the notice related to this standard. An April filing had given it until October 19 to regain compliance, setting 10 consecutive days as the condition. The published filing did not explain how Nasdaq addressed the matter after the stated compliance date came later than the end of the deadline. The company said the initial notice did not immediately affect the listing of its shares. The ticker NXGL remained listed on the Nasdaq Capital Market.
The deadline began after Nasdaq notified the company that its bid price was deficient, and the rules allowed 180 calendar days, through October 19, 2026, to remedy the deficiency. If it did not regain compliance within the initial period, the company could have been eligible for an additional 180 days, provided it met the other listing requirements. The April filing set the remedy standard as a closing bid price of at least $1 for 10 consecutive business days. Nasdaq’s latest letter removes the specific notice related to the price threshold. The available filing does not explain how the date falling beyond the initial deadline was handled. The company’s outcome remains tied to meeting this standard, according to its announcement.
The compliance restoration followed a 1-for-20 reverse stock split, which took effect on October 12. The move reduced shares outstanding from 9,747,663 on October 9 to approximately 487,384, before accounting for rounding of fractional shares. The stock continued to trade under the ticker NXGL on the Nasdaq Capital Market. The split terms provided for any resulting fractional share to be rounded up to the nearest whole share, with no cash paid in lieu. Share counts and conversion or exercise prices for convertible or exercisable securities were also adjusted. The split places the company’s efforts to address the price requirement in context, while it does not in itself change the operating results it disclosed.
In its second-quarter results, the company reported revenue of $3.69 million, compared with $2.70 million in the same period of 2025. Net loss was $2.87 million, versus $1.62 million a year earlier. NEXGEL said the integration of acquired businesses and the growth in related revenue proceeded more slowly than expected. Product launch initiatives and expansion in the surgical channel also lagged the original plan. These challenges mean the restoration of the listing requirement came alongside continued pressure on business execution. In its filing, the company did not link its remedy of the Nasdaq requirement to an improvement in operating results.
The company attributed some of the challenges to supply chain constraints that affected product availability. It said these constraints contributed to a backlog of approximately $795,000 at its BioNX Surgical division when it announced second-quarter results on August 17. The figure reflects the volume of orders that were not fulfilled on time amid supply difficulties, while the company said expansion in the surgical channel was slower than expected. This provides operating context for the compliance restoration, a step related to the bid price that does not by itself address supply constraints or the pace of expansion. The company had also cited slower progress integrating acquired businesses and growing related revenue. Addressing those issues remains separate from closing the price notice.